---
schema_version: "secwatch.filing_event.v1"
accession: "0001743881-26-000026"
form_type: "8-K"
ticker: "BBIO"
cik: "0001743881"
company_name: "BridgeBio Pharma, Inc."
filed_at: "2026-08-10T20:03:45+00:00"
generated_at: "2026-08-10T20:05:19.294292+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# BridgeBio Q2 revenue $243.7M, Attruby $222.4M; net loss $152.2M

## Summary
- Q2 total revenue $243.7M vs $110.6M YoY; US Attruby net product revenue $222.4M.
- Net loss attributable to common stockholders $152.2M ($0.78/share) vs $181.9M ($0.95) year-ago.
- Cash and marketable securities $720.2M at Jun 30; $1B preferred equity closed Jul 1 led by Sixth Street.
- NDAs: BBP-418 PDUFA Nov 27 2026 (Priority Review), encaleret May 8 2027, infigratinib submitted.
- Real-world data: acoramidis 37% reduction in composite CV events vs tafamidis (TriNetX, p=0.002).

## SEC filing metadata
- accession: 0001743881-26-000026
- form_type: 8-K
- ticker: BBIO
- cik: 0001743881
- company_name: BridgeBio Pharma, Inc.
- filed_at: 2026-08-10T20:03:45+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1743881/000174388126000026/0001743881-26-000026-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1743881/000174388126000026/bbio-20260810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001743881-26-000026
- JSON: https://secwatch.observer/filing/0001743881-26-000026.json
- Plain text: https://secwatch.observer/filing/0001743881-26-000026.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.